CUA Educational Content

New approaches to mUC treatment in 2024

Speakers: Normand Blais & Srikala Sridhar

Objectives:

By participating in this learning program, healthcare providers can expect to:

  • Discuss general statistics around bladder cancer and recent changes to the staging system.
  • Define who is eligible for cisplatin, carboplatin, and/or EV+P
  • How do we approach a 1L la/mUC treatment in 2024
  • How do we manage node positive disease
  • What are future directions in the field?
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

-------------------------------------

This program has received financial support in the form of an educational grant from Pfizer.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy